Panel speakers include life sciences investment experts from Civilization Ventures, Amgen Ventures, Canaan Partners, BEDB and Samsara BioCapital
London / San Francisco, 10 January 2020 - Global investment research, investor relations and consulting firm Edison Group is delighted to announce the line up for their panel session during their annual Healthcare Week in San Francisco.
On Tuesday 14 January from 8-10 am, Edison will be hosting a US investor panel in conjunction with leading international law firm Penningtons Manches Cooper. The panel presents an exciting opportunity for private companies to hear directly from the U.S. venture capital and private equity community on their perceptions of the UK life sciences industry, providing valuable insight into what they are looking for in both deals and pitches.
The U.S. offers private life sciences companies access to huge pools of potential capital. Edison’s extensive experience in the field has shown that having U.S.-based investors not only to provide funding but also make local introductions with the right stakeholders can be a vital contributor to both the funding and operational success of a company.
Once again, Edison’s presence in San Francisco will be an ideal opportunity for investors to meet the firm’s market-leading clients across all disciplines in the healthcare sector. Speakers on the Edison investor panel this year include: Shahram Seyedin-Noor (founder and general partner at Civilization Ventures), Janis Naeve (managing director at Amgen Ventures), Brent Ahrens (general partner at Canaan Partners), David Parker (inward investment specialist at BEDB) and Cory Freedland (principle at Samsara BioCapital), alongside Penningtons Manches Cooper representatives Ross McNaughton (Specialist tech & life sciences lawyer), Rob Hayes (Partner) and Chris Shelley (IP, commercial and competition partner).
Oliver Haslam, Director at Edison Group said: “This panel is another example of Edison Group’s continued focus on building strong investor relationships and helping private companies gain valuable insight into the US VC/PE community. Our aim has always been to play a positive, constructive role in the life sciences industry, where we see immense potential for growth and innovation.”
Rachel Carroll, President, Managing Partner at Edison Inc. added: “Edison’s US investor networks are actively seeking compelling investment opportunities in Europe. This prestigious panel will provide intelligent insight into how European life sciences companies can most effectively access the huge pools of potential capital in the United States, with practical advice from decision-makers within the West Coast venture capital and private equity community.”
- Ends -
For media enquiries, please contact:
Edison Group
Richard Morgan Evans, Borja Miquel, Samuel Du Bois
P: +44 20 3195 3240
About Edison:
Edison is an investment research, investor relations and consulting firm, with offices in North America, Europe, the Middle-East and Asia-Pacific. The heart of Edison is its world-renowned equity research platform and deep multi-sector expertise. Edison’s research is widely read by international investors, advisors and stakeholders. Edison leverages its core research platform to provide differentiated services including investor relations and strategic consulting.
For more information: www.edisongroup.com
Edison is authorised and regulated by the Financial Conduct Authority (FCA).
